908 Devices Inc.
MASS Nasdaq Laboratory Analytical Instruments Financials FY2020βFY2025
What 908 Devices Inc. does
No business description yet.
- Legal name
- 908 Devices Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 9, 2026
- Accession Β· CIK
- 0001104659-26-024877
0001555279
Revenue and margins
908 Devices Inc. had $56.2M of revenue in fiscal 2025, up 17.7% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$24.6M in fiscal 2025, β43.9% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
908 Devices Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 5.3%.
Balance sheet
Cash, debt and the ratios that show how comfortably 908 Devices Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $224M | $188M | $146M | $69.6M | $113M |
| Debt incl. finance leases | $15.0M | $15.0M | β | β | β |
| Debt / equity | 0.1x | 0.1x | β | β | β |
| Interest coverage | β45.4x | β274.3x | β212.7x | β | β |
| Current ratio | 17.0x | 11.2x | 7.7x | 4.1x | 4.2x |
| Quick ratio | 16.5x | 10.6x | 7.0x | 3.7x | 3.9x |
| Total assets | $261M | $243M | $203M | $159M | $190M |
| Total liabilities | $46.3M | $52.0M | $37.5M | $44.9M | $46.4M |
| Shareholders' equity | $215M | $191M | $165M | $115M | $144M |
| Net debt (β = net cash) | β$209M | β$173M | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 9 | 3 / 9 | 2 / 8 | 3 / 8 | 3 / 8 |
| Accruals ratio | β9.5% | 3.1% | β5.0% | β5.1% | β23.2% | 24.7% |
| Altman Z'' | 7.89 | 9.03 | 6.38 | 5.37 | β1.50 | 1.84 |
6 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $26.9M | $42.2M | $46.9M | $50.2M | $47.7M | $56.2M |
| Gross profit | $14.9M | $23.2M | $26.0M | $25.3M | $24.5M | $28.4M |
| Research and development | $8.2M | $13.1M | $17.5M | $21.9M | $15.0M | $15.6M |
| Operating income | β$5.8M | β$22.1M | β$35.4M | β$42.8M | β$57.4M | β$39.4M |
| Interest expense | $1.0M | $0.5M | $0.1M | $0.2M | β | β |
| Pretax income | β | β | β$33.6M | β$36.6M | β$53.1M | β$33.3M |
| Income tax | β | β | $0.0M | β$0.2M | β$0.3M | β$0.1M |
| Net income | β$12.8M | β$22.2M | β$33.6M | β$36.4M | β$72.2M | $19.5M |
| Net income to common | β$12.9M | β$22.2M | β | β | β$72.2M | $19.5M |
| Diluted EPS | β$2.35 | β$0.79 | β$1.07 | β$1.13 | β$2.12 | $0.54 |
| Diluted shares | 0.01B | 0.03B | 0.03B | 0.03B | 0.03B | 0.04B |
| Cash flow | ||||||
| Cash from operations | $4.1M | β$29.1M | β$20.9M | β$25.1M | β$30.2M | β$23.7M |
| Capital expenditure | $0.0M | $0.7M | $2.0M | $2.0M | $0.6M | $1.0M |
| Free cash flow | $4.1M | β$29.8M | β$23.0M | β$27.1M | β$30.8M | β$24.6M |
| Depreciation and amortization | $0.8M | $0.9M | $1.6M | $2.4M | $4.7M | $4.5M |
| Stock-based compensation | $0.5M | $2.5M | $7.2M | $9.8M | $11.8M | $9.8M |
| Acquisitions | β | β | $13.8M | β | β | β |
| Balance sheet | ||||||
| Cash and short-term investments | $159M | $224M | $188M | $146M | $69.6M | $113M |
| Total debt | $14.8M | $15.0M | $15.0M | β | β | β |
| Current assets | $171M | $253M | $216M | $174M | $103M | $145M |
| Current liabilities | $10.8M | $14.8M | $19.2M | $22.5M | $25.1M | $34.1M |
| Inventory | $4.6M | $7.9M | $12.5M | $14.9M | $10.9M | $13.0M |
| Property and equipment, net | $0.9M | $1.6M | $3.1M | $3.3M | $1.6M | $4.2M |
| Goodwill | β | β | $10.1M | $10.4M | $0.0M | $0.0M |
| Intangible assets | β | β | $8.5M | $7.9M | $38.7M | $36.4M |
| Total assets | $179M | $261M | $243M | $203M | $159M | $190M |
| Total liabilities | $39.8M | $46.3M | $52.0M | $37.5M | $44.9M | $46.4M |
| Preferred stock | $0.0M | β | β | β | β | β |
| Shareholders' equity | $139M | $215M | $191M | $165M | $115M | $144M |
| Margins | ||||||
| Gross margin | 55.5% | 55.0% | 55.5% | 50.4% | 51.3% | 50.6% |
| Operating margin | β21.6% | β52.3% | β75.5% | β85.1% | β120.2% | β70.1% |
| EBITDA margin | β18.5% | β50.1% | β72.1% | β80.4% | β110.4% | β62.2% |
| Net margin | β47.7% | β52.5% | β71.6% | β72.5% | β151.2% | 34.7% |
| FCF margin | 15.3% | β70.7% | β49.0% | β54.0% | β64.6% | β43.9% |
| Returns | ||||||
| Return on capital | β | β315.2% | β162.7% | β | β | β |
| Return on capital employed | β3.5% | β9.0% | β15.8% | β23.7% | β42.7% | β25.3% |
| Return on equity | β9.2% | β12.5% | β16.6% | β20.4% | β51.6% | 15.1% |
| Return on assets | β7.2% | β10.1% | β13.3% | β16.3% | β39.8% | 11.2% |
| Return on tangible equity | β9.3% | β10.3% | β19.5% | β24.7% | β95.1% | 18.2% |
| Growth | ||||||
| Revenue growth | β | 56.9% | 11.0% | 7.2% | β4.9% | 17.7% |
| FCF growth | β | β823.4% | β | β | β | β |
| Share count change | β | 409.7% | 12.6% | 2.4% | 5.7% | 5.3% |
| Financial health | ||||||
| Debt / equity | 0.1x | 0.1x | 0.1x | β | β | β |
| Interest coverage | β6.0x | β45.4x | β274.3x | β212.7x | β | β |
| Current ratio | 15.8x | 17.0x | 11.2x | 7.7x | 4.1x | 4.2x |
| Quick ratio | 15.4x | 16.5x | 10.6x | 7.0x | 3.7x | 3.9x |
| Capital allocation | ||||||
| Capex / revenue | 0.0% | 1.7% | 4.4% | 4.1% | 1.3% | 1.7% |
| Stock comp / revenue | 2.0% | 5.9% | 15.4% | 19.5% | 24.6% | 17.5% |
| Quality scores | ||||||
| Piotroski F-score | β | 3.0 | 3.0 | 2.0 | 3.0 | 3.0 |
| Altman Z'' | 7.9 | 9.0 | 6.4 | 5.4 | β1.5 | 1.8 |
| Accruals ratio | β9.5% | 3.1% | β5.0% | β5.1% | β23.2% | 24.7% |
Source: SEC EDGAR XBRL filings (CIK 0001555279). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.